Nusrat Jihan Begum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nusrat Jihan Begum has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Ambros J. Beer
Department of Nuclear Medicine, Ulm University, Ulm, Germany
2 shared publications- Gerhard Glatting
Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany
2 shared publications Matthias Eiber
Klinikum rechts der Isar, Department of Nuclear Medicine, Technical University of Munich School of Medicine, München, Germany
2 shared publicationsPeter Kletting
Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany
2 shared publicationsHans-Jürgen Wester
Technical University of Munich, Pharmaceutical Radiochemistry, Munich, Germany
1 shared publication
Latest Publications
- 16 October 2020
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 60 (01) , 33-37
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands
Aim The aim of this work was to systematically investigate the influence of the radionuclide half-life and affinity of prostate-specific membrane antigen (PSMA)-targeting ligands on the activity concentration for PET/CT imaging. Methods A whole-body physiologically-based pharmacokinetic (PBPK) model with individually estimated parameters of 13 patients with metastatic castration-resistant prostate cancer (mCRPC) was used to simulate the pharmacokinetics of PSMA-targeting radioligands. The simulations were performed with 68Ga (T1/2 = 1.13 h), 18F (T1/2 = 1.83 h), 64Cu (T1/2 = 12.7 h) and for different affinities (dissociation constants KD of 1–0.01 nM) and a commonly used ligand amount of 3 nmol. The activity concentrations were calculated at 1, 2, 3, 4, 8, 12, and 16 h after injection. Results The highest tumor uptake was achieved 1 h p. i. for 68Ga-PSMA. For 18F-PSMA, the highest tumor uptake was at 1 h p. i. and 2 h p.i for dissociation constants KD = 1 nM and KD = 0.1–0.01 nM, respectively. For 64Cu-PSMA, the highest tumor uptake was at 4 h p. i. for dissociation constant KD = 1 nM and at 4 h p. i. (9 patients) and 8 h p. i. (4 patients) for higher affinities. Compared to 68Ga-PSMA (1 h p. i.), the activity concentrations in the tumor for 18F-PSMA (2 h p. i.) increased maximum 1.3-fold with minor differences for all affinities. For 64Cu-PSMA (4 h p. i.), the improvements were in the range of 2.8 to 3.2-fold for all affinities. Conclusions The simulations indicate that the highest tumor-to-background ratio can be achieved after 4 hours in PET/CT using high-affinity 64Cu-PSMA. Ziel Ziel dieser Arbeit war es, den Einfluss der Radionuklid-Halbwertszeit und der Affinität von Prostata-spezifischen Membranantigen (PSMA)-adressierten Radioliganden auf die Aktivitätskonzentration für die PET/CT-Bildgebung systematisch zu untersuchen. Material und Methoden Ein physiologisch-basiertes pharmakokinetisches Ganzkörpermodell (PBPK) mit individuell geschätzten Parametern von 13 Patienten mit metastasiertem, kastrationsresistentem Prostatakarzinom (mCRPC) wurde verwendet, um die Pharmakokinetik von PSMA-adressierten Radioliganden zu simulieren. Die Simulationen wurden mit 68Ga (T1/2 = 1,13 h), 18F (T1/2 = 1,83 h), 64Cu (T1/2 = 12,7 h) und für verschiedene Affinitäten (Dissoziationskonstanten KD von 1–0,01 nM) und einer gebräuchlichen Ligandenmenge von 3 nmol durchgeführt. Die Aktivitätskonzentrationen wurden 1, 2, 3, 4, 8, 12 und 16 h nach Injektion berechnet. Ergebnisse Die höchste Tumoraufnahme wurde 1 h p. i. für 68Ga-PSMA erzielt. Für 18F-PSMA war die höchste Tumoraufnahme 1 h p. i. für die Dissoziationskonstanten KD = 1 nM bzw. 2 h p. i. für KD = 0,1–0,01 nM. Für 64Cu-PSMA war die höchste Tumoraufnahme 4 h p. i. für die Dissoziationskonstante KD = 1 nM und 4 h p. i. (9 Patienten) bzw. 8 h p. i. (4 Patienten) für höhere Affinitäten. Im Vergleich zu 68Ga -PSMA (1 h p. i.) erhöhten sich die Aktivitätskonzentrationen im Tumor für 18F-PSMA (2 h p. i.) maximal um das 1,3-fache mit geringen Unterschieden für alle Affinitäten. Bei 64Cu-PSMA (4 Std. p. i.) lagen die Verbesserungen bei allen Affinitäten im Bereich des 2,8- bis 3,2-fachen. Schlussfolgerung Die Simulationen zeigen, dass die höchste Tumor-to-Background-Ratio nach 4 Stunden im PET/CT mit hochaffinem 64Cu-PSMA erreicht werden kann. Received: 10 June 2020 Accepted: 02 September 2020 Article published online: 16 October 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 16 October 2020
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 60 (01) , 33-37
An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands
Aim The aim of this work was to systematically investigate the influence of the radionuclide half-life and affinity of prostate-specific membrane antigen (PSMA)-targeting ligands on the activity concentration for PET/CT imaging. Methods A whole-body physiologically-based pharmacokinetic (PBPK) model with individually estimated parameters of 13 patients with metastatic castration-resistant prostate cancer (mCRPC) was used to simulate the pharmacokinetics of PSMA-targeting radioligands. The simulations were performed with 68Ga (T1/2 = 1.13 h), 18F (T1/2 = 1.83 h), 64Cu (T1/2 = 12.7 h) and for different affinities (dissociation constants KD of 1–0.01 nM) and a commonly used ligand amount of 3 nmol. The activity concentrations were calculated at 1, 2, 3, 4, 8, 12, and 16 h after injection. Results The highest tumor uptake was achieved 1 h p. i. for 68Ga-PSMA. For 18F-PSMA, the highest tumor uptake was at 1 h p. i. and 2 h p.i for dissociation constants KD = 1 nM and KD = 0.1–0.01 nM, respectively. For 64Cu-PSMA, the highest tumor uptake was at 4 h p. i. for dissociation constant KD = 1 nM and at 4 h p. i. (9 patients) and 8 h p. i. (4 patients) for higher affinities. Compared to 68Ga-PSMA (1 h p. i.), the activity concentrations in the tumor for 18F-PSMA (2 h p. i.) increased maximum 1.3-fold with minor differences for all affinities. For 64Cu-PSMA (4 h p. i.), the improvements were in the range of 2.8 to 3.2-fold for all affinities. Conclusions The simulations indicate that the highest tumor-to-background ratio can be achieved after 4 hours in PET/CT using high-affinity 64Cu-PSMA. Ziel Ziel dieser Arbeit war es, den Einfluss der Radionuklid-Halbwertszeit und der Affinität von Prostata-spezifischen Membranantigen (PSMA)-adressierten Radioliganden auf die Aktivitätskonzentration für die PET/CT-Bildgebung systematisch zu untersuchen. Material und Methoden Ein physiologisch-basiertes pharmakokinetisches Ganzkörpermodell (PBPK) mit individuell geschätzten Parametern von 13 Patienten mit metastasiertem, kastrationsresistentem Prostatakarzinom (mCRPC) wurde verwendet, um die Pharmakokinetik von PSMA-adressierten Radioliganden zu simulieren. Die Simulationen wurden mit 68Ga (T1/2 = 1,13 h), 18F (T1/2 = 1,83 h), 64Cu (T1/2 = 12,7 h) und für verschiedene Affinitäten (Dissoziationskonstanten KD von 1–0,01 nM) und einer gebräuchlichen Ligandenmenge von 3 nmol durchgeführt. Die Aktivitätskonzentrationen wurden 1, 2, 3, 4, 8, 12 und 16 h nach Injektion berechnet. Ergebnisse Die höchste Tumoraufnahme wurde 1 h p. i. für 68Ga-PSMA erzielt. Für 18F-PSMA war die höchste Tumoraufnahme 1 h p. i. für die Dissoziationskonstanten KD = 1 nM bzw. 2 h p. i. für KD = 0,1–0,01 nM. Für 64Cu-PSMA war die höchste Tumoraufnahme 4 h p. i. für die Dissoziationskonstante KD = 1 nM und 4 h p. i. (9 Patienten) bzw. 8 h p. i. (4 Patienten) für höhere Affinitäten. Im Vergleich zu 68Ga -PSMA (1 h p. i.) erhöhten sich die Aktivitätskonzentrationen im Tumor für 18F-PSMA (2 h p. i.) maximal um das 1,3-fache mit geringen Unterschieden für alle Affinitäten. Bei 64Cu-PSMA (4 Std. p. i.) lagen die Verbesserungen bei allen Affinitäten im Bereich des 2,8- bis 3,2-fachen. Schlussfolgerung Die Simulationen zeigen, dass die höchste Tumor-to-Background-Ratio nach 4 Stunden im PET/CT mit hochaffinem 64Cu-PSMA erreicht werden kann. Received: 10 June 2020 Accepted: 02 September 2020 Article published online: 16 October 2020 © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 27 December 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castration-resistant prostate cancer were analysed. Simulations were performed for different combinations of association rates kon (0.1–0.01 L/nmol/min), dissociation rates koff (0.1–0.0001 min−1), internalization rates λint (0.01–0.0001 min−1) and ligand amounts (1–1000 nmol). For imaging the activity was normalized to volume and injected activity (68Ga-PSMA at 1 h). For therapy the absorbed dose was calculated for 7.3 ± 0.3 GBq 177Lu-PSMA. The effect of the investigated parameters on therapy were larger compared to imaging. For imaging, the combination of properties leading to the highest tumour uptake was kon = 0.1 L/nmol/min, koff = 0.01 min−1 for typical ligand amounts (1–10 nmol). For therapy, the higher the internalization rate, the larger was the required ligand amount for optimal tumour-to-kidney ratios. The higher the affinity, the more important was the choice of the optimal ligand amount. PBPK modelling provides insight into the pharmacokinetics of PSMA-specific ligands. Further in silico and in vivo studies are required to verify the influence of the analysed parameters.
- 27 December 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-8
Open AccessThe effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castration-resistant prostate cancer were analysed. Simulations were performed for different combinations of association rates kon (0.1–0.01 L/nmol/min), dissociation rates koff (0.1–0.0001 min−1), internalization rates λint (0.01–0.0001 min−1) and ligand amounts (1–1000 nmol). For imaging the activity was normalized to volume and injected activity (68Ga-PSMA at 1 h). For therapy the absorbed dose was calculated for 7.3 ± 0.3 GBq 177Lu-PSMA. The effect of the investigated parameters on therapy were larger compared to imaging. For imaging, the combination of properties leading to the highest tumour uptake was kon = 0.1 L/nmol/min, koff = 0.01 min−1 for typical ligand amounts (1–10 nmol). For therapy, the higher the internalization rate, the larger was the required ligand amount for optimal tumour-to-kidney ratios. The higher the affinity, the more important was the choice of the optimal ligand amount. PBPK modelling provides insight into the pharmacokinetics of PSMA-specific ligands. Further in silico and in vivo studies are required to verify the influence of the analysed parameters.